{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:56:41Z","timestamp":1787169401525,"version":"build-2736575974"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.soc.2020.02.010","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T18:27:14Z","timestamp":1590776834000},"page":"485-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Role of Surgery in Stage IV Melanoma"],"prefix":"10.1016","volume":"29","author":[{"given":"Conor H.","family":"O\u2019Neill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"McMasters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.soc.2020.02.010_bib1","series-title":"Cancer facts & figures 2019","year":"2019"},{"issue":"1","key":"10.1016\/j.soc.2020.02.010_bib2","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.soc.2020.02.010_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.soc.2020.02.010_bib4","first-page":"193","article-title":"Prognostic factors in 1,521 melanoma patients with distant metastases","volume":"181","author":"Barth","year":"1995","journal-title":"J\u00a0Am Coll Surg"},{"issue":"3","key":"10.1016\/j.soc.2020.02.010_bib5","first-page":"295","article-title":"Metastasectomy in malignant melanoma","volume":"115","author":"Karakousis","year":"1994","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.soc.2020.02.010_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/(SICI)1096-9098(199908)71:4<209::AID-JSO1>3.0.CO;2-2","article-title":"Metastasectomy for recurrent stage IV melanoma","volume":"71","author":"Ollila","year":"1999","journal-title":"J\u00a0Surg Oncol"},{"issue":"18_suppl","key":"10.1016\/j.soc.2020.02.010_bib7","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1200\/jco.2006.24.18_suppl.8019","article-title":"Surgical resection for stage IV melanoma: A Southwest Oncology Group trial (S9430)","volume":"24","author":"Sondak","year":"2006","journal-title":"J Clin Oncol."},{"issue":"13","key":"10.1016\/j.soc.2020.02.010_bib8","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1245\/s10434-017-6072-3","article-title":"Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases","volume":"24","author":"Faries","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2020.02.010_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jso.25326","article-title":"Indications for the surgical resection of stage IV disease","volume":"119","author":"Bello","year":"2019","journal-title":"J\u00a0Surg Oncol"},{"issue":"4","key":"10.1016\/j.soc.2020.02.010_bib10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s10434-999-0336-5","article-title":"Surgery for melanoma metastatic to the gastrointestinal tract","volume":"6","author":"Agrawal","year":"1999","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.soc.2020.02.010_bib11","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1245\/s10434-012-2398-z","article-title":"Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I)","volume":"19","author":"Howard","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"21","key":"10.1016\/j.soc.2020.02.010_bib12","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.soc.2020.02.010_bib13","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.soc.2020.02.010_bib14","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.soc.2020.02.010_bib15","first-page":"21","article-title":"Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview","volume":"19","author":"Serrone","year":"2000","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.soc.2020.02.010_bib16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/1097-0142(19840315)53:6<1299::AID-CNCR2820530613>3.0.CO;2-4","article-title":"Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)","volume":"53","author":"Hill","year":"1984","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.soc.2020.02.010_bib17","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.soc.2020.02.010_bib18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"35","key":"10.1016\/j.soc.2020.02.010_bib19","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","volume":"26","author":"Atkins","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.soc.2020.02.010_bib20","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1200\/JCO.2005.03.202","article-title":"Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group","volume":"23","author":"Keilholz","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2020.02.010_bib21","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1200\/JCO.2002.07.044","article-title":"Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial","volume":"20","author":"Eton","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"34","key":"10.1016\/j.soc.2020.02.010_bib22","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1200\/JCO.2007.12.0253","article-title":"Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients","volume":"25","author":"Ives","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2020.02.010_bib23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.soc.2020.02.010_bib24","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.soc.2020.02.010_bib25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.soc.2020.02.010_bib26","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in resected Stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.soc.2020.02.010_bib27","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.soc.2020.02.010_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.soc.2020.02.010_bib29","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","article-title":"Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study","volume":"15","author":"Ribas","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.soc.2020.02.010_bib30","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9839","key":"10.1016\/j.soc.2020.02.010_bib31","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.soc.2020.02.010_bib32","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene Laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2020.02.010_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2051-1426-2-11","article-title":"Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma","volume":"2","author":"Kaufman","year":"2014","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.soc.2020.02.010_bib34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther"},{"issue":"3","key":"10.1016\/j.soc.2020.02.010_bib35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1084\/jem.187.3.341","article-title":"Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T\u00a0cell response","volume":"187","author":"Goldsmith","year":"1998","journal-title":"J\u00a0Exp Med"},{"issue":"25","key":"10.1016\/j.soc.2020.02.010_bib36","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.soc.2020.02.010_bib37","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.soc.2020.02.010_bib38","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2018.36.15_suppl.9508","article-title":"Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL)","volume":"36","author":"Andtbacka","year":"2018","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.soc.2020.02.010_bib39","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.soc.2020.02.010_bib40","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/archsurg.139.9.961","article-title":"Contemporary surgical treatment of advanced-stage melanoma","volume":"139","author":"Essner","year":"2004","journal-title":"Arch Surg"},{"issue":"4","key":"10.1016\/j.soc.2020.02.010_bib41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/(SICI)1096-9098(199812)69:4<206::AID-JSO3>3.0.CO;2-N","article-title":"Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma","volume":"69","author":"Ollila","year":"1998","journal-title":"J\u00a0Surg Oncol"},{"issue":"11","key":"10.1016\/j.soc.2020.02.010_bib42","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(06)70938-X","article-title":"Complete metastasectomy in patients with stage IV metastatic melanoma","volume":"7","author":"Ollila","year":"2006","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.soc.2020.02.010_bib43","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/jso.23938","article-title":"Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication","volume":"111","author":"He","year":"2015","journal-title":"J\u00a0Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2020.02.010_bib44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jamcollsurg.2014.04.008","article-title":"A\u00a020-year experience of hepatic resection for melanoma: is there an expanding role?","volume":"219","author":"Faries","year":"2014","journal-title":"J\u00a0Am Coll Surg"},{"issue":"36","key":"10.1016\/j.soc.2020.02.010_bib45","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2020.02.010_bib46","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/jso.21961","article-title":"Rationale for complete metastasectomy in patients with stage IV metastatic melanoma","volume":"104","author":"Ollila","year":"2011","journal-title":"J\u00a0Surg Oncol"},{"issue":"15_suppl","key":"10.1016\/j.soc.2020.02.010_bib47","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps9094","article-title":"Phase 2, multicenter, randomized, open label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB\/C and IVM1a melanoma (MEL)","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol."},{"issue":"15_suppl","key":"10.1016\/j.soc.2020.02.010_bib48","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.1200\/JCO.2019.37.15_suppl.9587","article-title":"Neoadjuvant cytoreductive treatment with BRAF\/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection: REDUCTOR trial","volume":"37","author":"Blankenstein","year":"2019","journal-title":"J Clin Oncol."},{"issue":"15_suppl","key":"10.1016\/j.soc.2020.02.010_bib49","doi-asserted-by":"crossref","first-page":"9586","DOI":"10.1200\/JCO.2017.35.15_suppl.9586","article-title":"Neoadjuvant ipilimumab 1 nivolumab (IPI1NIVO) in palpable stage III melanoma: updated data from the OpACIN trial and first immunological analyses","volume":"35","author":"Rozeman","year":"2017","journal-title":"J Clin Oncol."},{"issue":"5","key":"10.1016\/j.soc.2020.02.010_bib50","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1054\/bjoc.2000.1335","article-title":"Lung metastases from melanoma: when is surgical treatment warranted?","volume":"83","author":"Leo","year":"2000","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.soc.2020.02.010_bib51","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1010-7940(02)00026-X","article-title":"Pulmonary metastatic melanoma -- the survival benefit associated with positron emission tomography scanning","volume":"21","author":"Dalrymple-Hay","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"10.1016\/j.soc.2020.02.010_bib52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jtcvs.2006.08.065","article-title":"Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma","volume":"133","author":"Petersen","year":"2007","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"9","key":"10.1016\/j.soc.2020.02.010_bib53","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/archsurg.1996.01430210073013","article-title":"Surgical resection for melanoma metastatic to the gastrointestinal tract","volume":"131","author":"Ollila","year":"1996","journal-title":"Arch Surg"},{"issue":"7","key":"10.1016\/j.soc.2020.02.010_bib54","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10434-999-0633-z","article-title":"Long-term survival after complete resection of melanoma metastatic to the adrenal gland","volume":"6","author":"Haigh","year":"1999","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2020.02.010_bib55","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.amjsurg.2007.12.018","article-title":"Melanoma adrenal metastasis: natural history and surgical management","volume":"195","author":"Mittendorf","year":"2008","journal-title":"Am J Surg"},{"issue":"1","key":"10.1016\/j.soc.2020.02.010_bib56","first-page":"11","article-title":"Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma","volume":"88","author":"Sampson","year":"1998","journal-title":"J\u00a0Neurosurg"},{"issue":"2","key":"10.1016\/j.soc.2020.02.010_bib57","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PPO.0b013e31824bc981","article-title":"Surgery for distant melanoma metastasis","volume":"18","author":"Leung","year":"2012","journal-title":"Cancer J"},{"issue":"7","key":"10.1016\/j.soc.2020.02.010_bib58","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2020.02.010_bib59","unstructured":"Bello DM, Panageas KS, Hollmann TJ, et\u00a0al. Outcomes of patients with metastatic melanoma selected for surgery after immunotherapy (Abstract 5). Society of Surgical Oncology Annual Cancer Symposium. 2018."},{"issue":"6230","key":"10.1016\/j.soc.2020.02.010_bib60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.soc.2020.02.010_bib61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1245\/s10434-016-5537-0","article-title":"Metastasectomy following immunotherapy with adoptive cell transfer for patients with advanced melanoma","volume":"24","author":"Klemen","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"10.1016\/j.soc.2020.02.010_bib62","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1158\/1078-0432.CCR-10-1507","article-title":"Successful treatment of melanoma brain metastases with adoptive cell therapy","volume":"16","author":"Hong","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.soc.2020.02.010_bib63","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/BF02574498","article-title":"The surgical management of metastatic melanoma","volume":"9","author":"Allen","year":"2002","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2020.02.010_bib64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00000658-198608000-00013","article-title":"Surgery as palliative treatment for distant metastases of melanoma","volume":"204","author":"Wornom","year":"1986","journal-title":"Ann Surg"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320720300211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320720300211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:02:58Z","timestamp":1760961778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320720300211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1055320720300211"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2020.02.010","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Surgery in Stage IV Melanoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2020.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}